MAFA: A Protein as A Drug Target and Biomarker (G389692)

Target Name: MAFA

NCBI ID: G389692

MAFA

MAFA: A Protein as A Drug Target and Biomarker

MAFA (myeloid-derived factor), also known as CD11b, is a protein that is expressed in the myeloid cells of the human body. It is a member of the integrin family and is involved in the regulation of cell adhesion, migration, and interactions with other cells and the immune system.

MAFA has been identified as a potential drug target and has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons for the interest in MAFA is its ability to interact with several different signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many diseases, including cancer, and MAFA has been shown to play a role in the regulation of TGF-β signaling in myeloid cells.

In addition to its role in TGF-β signaling, MAFA has also been shown to play a role in the regulation of several other signaling pathways, including the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation, and the NF-kappa-B signaling pathway, which is involved in inflammation and immune response.

The potential drug targets for MAFA are numerous and range from cell signaling pathways to cellular processes such as cell adhesion, migration, and invasion. Some of the potential drug targets for MAFA include inhibitors of the TGF-β pathway, anti-inflammatory agents, and agents that can modulate the activity of MAFA-containing proteins.

In addition to its potential as a drug target, MAFA is also a potential biomarker for several diseases. The myeloid-derived factor receptor (MDFR) is a transmembrane protein that is expressed in myeloid cells and is involved in the regulation of MAFA signaling. Blockade of the MDFR has been shown to be an effective way to treat multiple myeloma, a type of cancer that arises from the overproduction of white blood cells in the bone marrow.

Another potential biomarker for MAFA is the expression of MAFA in various tissues and organs, including the brain, which is involved in the regulation of MAFA signaling in this system. Elevated levels of MAFA have been observed in the brains of individuals with multiple myeloma, which suggests that this protein may be involved in the development and progression of this disease.

In conclusion, MAFA is a protein that has been identified as a potential drug target and biomarker for several diseases. Its ability to interact with multiple signaling pathways and its expression in various tissues and organs make it an attractive target for research and development of new treatments. Further research is needed to fully understand the role of MAFA in disease and to develop effective treatments.

Protein Name: MAF BZIP Transcription Factor A

Functions: Transcription factor that activates insulin gene expression (PubMed:15993959, PubMed:12011435). Acts synergistically with NEUROD1/BETA2 and PDX1 (PubMed:15993959). Binds the insulin enhancer C1/RIPE3b element (PubMed:12011435). Binds to consensus TRE-type MARE 5'-TGCTGACTCAGCA-3' DNA sequence (PubMed:23148532, PubMed:29339498)

The "MAFA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAFA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets